Thomas J. Schall, President and CEO at ChemoCentryx, Inc. (CCXI), sold 314,245 shares at $14.00 ($4.3M) on 2019-03-29, disclosed to the SEC on 2019-04-02.
Seasonal sale ($4.3M) by President and CEO — this insider has traded CCXI in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.00 | 5,755 | $81K | 1.9% |
| 2 | $13.58 | 79,259 | $1.1M | 25.0% |
| 3 | $13.58 | 79,259 | $1.1M | 25.0% |
| 4 | $13.85 | 74,986 | $1.0M | 24.1% |
| 5 | $13.85 | 74,986 | $1.0M | 24.1% |
| Total | $13.72 avg | 314,245 |
| $4.3M |
| 100% |
| Filing → |
| IMRX | BUY | 2025-06-18 | $179K | — | Filing → |
| IMRX | BUY | 2024-03-25 | $7K | — | Filing → |
| CCXI | SELL | 2022-08-08 | $6.5M | — | Filing → |